InnerPulse

About InnerPulse

InnerPulse, Inc. was a development-stage medical device company established in 2003, positioned to address the market for treating abnormal heart rhythms. The firm was founded by Dr. Richard Stack, a professor of cardiology at Duke University and a recognized figure in cardiovascular disease with a track record of co-founding multiple medical technology companies. The company's operations were based in the Research Triangle Park area of North Carolina, a hub for biotechnological and medical research.

The core of InnerPulse's business was the development of its Percutaneous Implantable Cardioverter Defibrillator (PICD), a device designed for patients with cardiac rhythm disorders. Unlike traditional implantable cardioverter-defibrillators (ICDs) that require a surgical pocket in the chest, the PICD was engineered to be implanted in a less invasive, catheter-based procedure entirely within the vascular system. This approach was intended to shorten procedure times, reduce post-implant discomfort, and make the device imperceptible to the patient. The product featured a flexible, hermetically sealed enclosure with titanium electrodes and custom-made batteries, reflecting a sophisticated engineering effort. The target clients for this technology were electrophysiologists and other implanting cardiologists, with the goal of expanding the number of physicians who could perform the procedure.

InnerPulse attracted substantial interest from strategic investors, securing $50 million in a Series C financing round in 2007, which followed an overall backing of $85 million. The investor syndicate was a formidable list of industry leaders, including Johnson & Johnson Development Corporation, Medtronic, Inc., Boston Scientific, and Frazier Healthcare Ventures. The capital was allocated to finalize the PICD's development and to build the necessary infrastructure for human clinical trials and eventual commercialization. At the helm was President and CEO Dan Pelak, a seasoned executive with over two decades of experience in the medical technology sector, notably at Medtronic and as CEO of Closure Medical Corporation.

Despite the significant funding and promising initial results in human feasibility studies, the company's trajectory was halted by setbacks in chronic animal trials. These studies revealed critical flaws, including lead dislodgement and perforation, which raised significant safety and reliability concerns. Consequently, key backer Boston Scientific shifted its support to a competing technology, Cameron Health's Subcutaneous ICD (S-ICD). Faced with insurmountable technical hurdles and the depletion of its financial resources, InnerPulse was unable to proceed with further development and chronic human trials. The company was ultimately dissolved, and it sold off its assets in 2011, marking the end of its ambitious endeavor.